Discovery of a Potent and Selective ROMK Inhibitor with Pharmacokinetic Properties Suitable for Preclinical Evaluation.
about
Discovery of MK-7145, an Oral Small Molecule ROMK Inhibitor for the Treatment of Hypertension and Heart Failure.Inhibition of ROMK blocks macula densa tubuloglomerular feedback yet causes renal vasoconstriction in anesthetized rats.The therapeutic potential of targeting the Kir1.1 (renal outer medullary K+) channel.Discovery and in Vitro Optimization of 3-Sulfamoylbenzamides as ROMK Inhibitors.
P2860
Discovery of a Potent and Selective ROMK Inhibitor with Pharmacokinetic Properties Suitable for Preclinical Evaluation.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Discovery of a Potent and Sele ...... le for Preclinical Evaluation.
@ast
Discovery of a Potent and Sele ...... le for Preclinical Evaluation.
@en
type
label
Discovery of a Potent and Sele ...... le for Preclinical Evaluation.
@ast
Discovery of a Potent and Sele ...... le for Preclinical Evaluation.
@en
prefLabel
Discovery of a Potent and Sele ...... le for Preclinical Evaluation.
@ast
Discovery of a Potent and Sele ...... le for Preclinical Evaluation.
@en
P2093
P2860
P356
P1476
Discovery of a Potent and Sele ...... le for Preclinical Evaluation.
@en
P2093
Aaron Corona
Adam Weinglass
Alexander Pasternak
Andrew M Swensen
Aurash Shahripour
Birgit T Priest
Brande Thomas-Fowlkes
Caryn Hampton
Emma Parmee
Gregory J Kaczorowski
P2860
P304
P356
10.1021/ML500440U
P577
2015-05-07T00:00:00Z